Alumis says envudeucitinib hits 54% PASI 100 at 48 weeks in ONWARD3 plaque psoriasis extension study

• Alumis reported topline long-term extension results for envudeucitinib in moderate-to-severe plaque psoriasis on Aug. 10, 2026.
• Patients on continued treatment showed rising rates of complete skin clearance over 48 weeks, supporting durable disease control with an oral therapy.
• Safety and tolerability stayed consistent with earlier Phase 3 trials, with no new safety signals flagged in the extension study.
• The group plans to present additional ONWARD program data at upcoming medical meetings.
• An FDA New Drug Application filing is targeted for 4Q 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Alumis Inc. published the original content used to generate this news brief on August 10, 2026, and is solely responsible for the information contained therein.